About: Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) wetenschappelijk artikel (nl) article scientifique publié en 2019 (fr) im April 2019 veröffentlichter wissenschaftlicher Artikel (de) наукова стаття, опублікована у квітні 2019 (uk)
publication date	wds:Q64080709-9B868843-D266-48CD-AD91-23C3BCCF17F9
publication date	2019-04-03 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q64080709-2AF5A93A-EF94-4F6F-9D41-0A47B1A4AFC1
language of work or name	English
exact match	wds:Q64080709-AC3F9B3D-B890-4BDA-A1A9-225D7A68137E
exact match	https://scigraph.springernature.com/pub.10.1186/s40425-019-0579-z
cites work	wds:Q64080709-10FA1568-4178-4384-8239-89B9A9770718 wds:Q64080709-1434DAF1-1163-4B54-B8B8-C9A5DE9E0310 wds:Q64080709-1E342786-26DC-4726-81F9-5D573414010D wds:Q64080709-256D1F99-7CF5-489A-8C82-BB936B2CE4F1 wds:Q64080709-295BBA22-03E1-443B-8780-3A8872E08B17 wds:Q64080709-353D667D-E2C4-4D84-ACD2-0EBB43D88DC9 wds:Q64080709-362993C0-DDD1-4073-B3FB-87E847368420 wds:Q64080709-42E5AEA2-A08E-40B2-9CBF-02DDA1125D6B wds:Q64080709-463A3939-6B90-46AB-9AAF-CC3572165F9E wds:Q64080709-4840C2F0-3984-41F1-A2B3-928870E567B7 wds:Q64080709-5AF7B61F-B123-419B-8210-B9B0F7105772 wds:Q64080709-60A79310-5FFA-44F9-BAAA-E1F2C60DDB53 wds:Q64080709-70BCCBAC-9CC4-43F0-99D7-65A750BB67B4 wds:Q64080709-758C4463-1B30-47D8-8C46-11A59C397294 wds:Q64080709-8C0513F9-5C82-40A6-9E99-F2461821283B wds:Q64080709-8E8572BC-D35D-42DF-AF7D-17762B8DEA6F wds:Q64080709-92BA432A-7239-452C-931A-07F2F940AD24 wds:Q64080709-97482CD7-784B-4EF0-8E1E-699CA7008B0F wds:Q64080709-9E9BFAE4-38AE-4248-BEAD-9C96CB8EC4D9 wds:Q64080709-C0569298-1269-4B42-A740-B499E8163E30 wds:Q64080709-C88118AE-D8F5-47F5-A686-BC8BBF6BCD9E wds:Q64080709-E56215F1-73F8-4E39-9A92-235F0E5D6DDC wds:Q64080709-E68FDF4F-5DA4-4361-BE05-303E2063B3B8 wds:Q64080709-F938B389-D0CC-4360-884F-166B70B6D4EA wds:Q64080709-FDCD100A-9FA3-4C69-858A-0E0E9659FA96 wds:Q64080709-FF9946C5-3B87-4BE6-B742-34B620171591
cites work	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center Immune-related adverse events with immune checkpoint blockade: a comprehensive review The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions. Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
author name string	wds:Q64080709-14E02144-BEA8-4B3D-A742-4C7E38532C0B wds:Q64080709-1E5DA6B8-F293-45AE-B3CF-7120F58CE4BC wds:Q64080709-2DD82212-E111-4ECC-90EF-F1F7C4532736 wds:Q64080709-4062FA8E-4B99-42FD-A03B-BBA5FBAED177 wds:Q64080709-41C77390-8696-4812-BFB5-EFEFD6AA4D56 wds:Q64080709-45BAFA30-3688-4739-90E7-AB80F61D029D wds:Q64080709-45FCC4BD-773C-4C73-86FF-0B8A538770BD wds:Q64080709-5269924C-F637-4DC6-BA1E-753385ECE7A7 wds:Q64080709-689DEB2D-FD08-4B57-AA9B-9584FFDEA716 wds:Q64080709-A32BF998-A0FC-484D-8A00-4A6C7564E0CC wds:Q64080709-AAF38352-9137-41A7-999F-F2BBC9F0433E wds:Q64080709-AF8EBB3C-1505-40C3-AF3F-C9A159D821C3 wds:Q64080709-B7006CEC-9542-4AF7-BE6F-D3D5A01E764A wds:Q64080709-CF132CD8-0E44-48FC-9728-28DF1E30A928 wds:Q64080709-D4AC7D5F-5394-4AF1-95C1-74CD800AC672 wds:Q64080709-DC26E1C7-368A-4A5B-A6D1-EFF596092171 wds:Q64080709-E4B7BA1C-CC50-437C-8229-50BE43E1F08F wds:Q64080709-F8649805-40EE-4C28-A09D-EB55DAF8BC87
author name string	Alessandra Raimondi Giacomo Cartenì Cora N Sternberg Camillo Porta Enrico Cortesi Federico Cappuzzo Francesco Cognetti Davide Tassinari Elena Verzoni Giuseppe Procopio Alberto Sobrero Sabrina Rossetti Roberto Sabbatini Antonio Pazzola Francesca Rastelli Stefano Panni Italian Nivolumab Renal Cell Cancer Early Access Program group Gianmarco Surico

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software